Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children-Reference-Cited by-同舟云学术

Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children

Published:2023-05-06 Issue:6 Volume:62 Page:891-904
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Cleary Yumi^ORCID,Kletzl Heidemarie,Grimsey Paul,Heinig Katja,Ogungbenro Kayode^ORCID,Silber Baumann Hanna Elisabeth,Frey Nicolas,Aarons Leon^ORCID,Galetin Aleksandra,Gertz Michael

Funder

F. Hoffmann-La Roche

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-023-01241-7.pdf

Reference41 articles.

1. Lefebvre S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155–65.

2. D’Amico A, et al. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71.

3. Ratni H, et al. Discovery of risdiplam, a selective survival of motor neuron-2 ( SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501–17.

4. European Medicines Agency. Evrysdi (risdiplam). 2021. https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-evrysdi_en.pdf. Accessed Feb 2022.

5. US FDA. FDA Approves Oral Treatment for Spinal Muscular Atrophy. 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-oral-treatment-spinal-muscular-atrophy. Accessed Nov 2022.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Facing the Facts of Altered Plasma Protein Binding: Do Current Models Correctly Predict Changes in Fraction Unbound in Special Populations?;Journal of Pharmaceutical Sciences;2024-06

2. Hepatocyte-intrinsic SMN deficiency drives metabolic dysfunction and liver steatosis in spinal muscular atrophy;Journal of Clinical Investigation;2024-05-09

3. Exploration of adverse events associated with risdiplam use: Retrospective cases from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database;PLOS ONE;2024-03-01

4. A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations;Journal of Pharmacokinetics and Pharmacodynamics;2024-02-03

5. Monoamine Oxidases and Flavin-Containing Monooxygenases;Reference Module in Biomedical Sciences;2024